• 2022年度
• 2021年度
• 2020年度
• 2019年度
• 2018年度
• 2017年度
• 2016年度
• 2015年度
• 2014年度
• 2013年度

2022年度論文業績

• Marumo A, Omori I, Tara S, Otsuka Y, Konuma R, Adachi H, Wada A, Kishida Y, Konishi T, Nagata A, Yamada Y, Nagata R, Noguchi Y, Toya T, Igarashi A, Najima Y, Kobayashi T, Yamaguchi H, Inokuchi K, Sakamaki H, Ohashi K, Doki N. Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less. Asia-Pacific Journal of Clinical Oncology. 2022;18(5):507-514.
• Aoyama R, Kubota Y, Tara S, Wakita S, Yamaguchi H, Shimizu W, Takano H. Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations.International heart journal. 2022:63(4) 661-668.
• Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. International Journal of Hematology 2022;116(2) 199-214.
• Arai K, Sakaguchi M, Yui S, Kitano T, Miyata M, Yogosawa M, Nakayama K, Tajika K, Usuki K, Kuroda J, Uoshima N, Kobayashi Y, Uchiyama H, Kubota Y, Kimura S, Mori S, Hirai M, i Wakita S, Yamaguchi H. Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320. International Journal of Laboratory Hematology 2022;44(6)1102-1110.
• Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Masuko M, Murata M, Tashiro H, Kako S, Satake A, Hagihara M, Ota S, Saito T, Kagawa K, Matsuo Y, Itonaga H, Uoshima N, Yamaguchi H, Naito K, Takahashi M, Fukuda T. Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation. Journal of cancer survivorship : research and practice 2022
• Sakaguchi M, Nagata Y, Terasaki Y, Takeyoshi A, Yasuda S, Honma S, Kinoshita R, Marumo A, Asayama T, Yui S, Wakita S, Okamoto M, Kajimoto Y, Inokuchi K, Yamaguchi H. Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with central nervous system symptoms. Journal of Nippon Medical School. 2022 ;101(11):2471-2476.
• Wakita S, Marumo A , Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer science 2023; 114(4):1297-1308.
• Yui S, Wakita S, Nagata Y, Kuribayashi Y, Asayama T, Fujiwara Y, Sakaguchi M, Yamanaka S, Marumo A, Omori I, Kinoshita R, Onai D, Sunakawa M, Kaito Y, Inai K, Tokura T, Takeyoshi A, Yasuda S, Honma S, Nakayama K, Hirakawa T, Arai K, Kitano T, Okamoto M, Inokuchi K, Yamaguchi H. Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study. Asia Pac J Clin Oncol.in press. 2023;19(1):136-138.
• Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study. International journal of hematology. 2023
• Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H, Inokuchi K, Tamura H. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental hematology. 2023